Renascience Inc. (TYO:4889)

Japan flag Japan · Delayed Price · Currency is JPY
1,446.00
-24.00 (-1.63%)
At close: Apr 17, 2026
Market Cap19.92B +38.7%
Revenue (ttm)107.00M -23.0%
Net Income-259.00M
EPS-20.35
Shares Out13.78M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume197,100
Average Volume337,785
Open1,468.00
Previous Close1,470.00
Day's Range1,438.00 - 1,496.00
52-Week Range992.00 - 3,310.00
Beta1.97
RSI36.75
Earnings DateMay 7, 2026

About Renascience

Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, PAI-1 inhibitor for the treatment of alopecia disease that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 3
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4889
Full Company Profile

Financial Performance

Financial Statements